Th2A and Th17 cell frequencies and regulatory markers as follow‐up biomarker candidates for successful multifood oral immunotherapy
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Foundation for the National Institutes of Health (5R01AI140134)
This publication has 9 references indexed in Scilit:
- A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic IndividualseClinicalMedicine, 2019
- The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy ResponsesClinical Reviews in Allergy & Immunology, 2018
- Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic toleranceJournal of Allergy and Clinical Immunology, 2017
- Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position PaperAllergy, 2017
- Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapyJournal of Allergy and Clinical Immunology, 2016
- Initial immunological changes as predictors for house dust mite immunotherapy responseClinical & Experimental Allergy, 2015
- Allergen‐specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapyClinical & Experimental Allergy, 2012
- A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapyJournal of Allergy and Clinical Immunology, 2012
- Stabilin‐1/CLEVER‐1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophagesEuropean Journal of Immunology, 2011